Stay updated on NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Sign up to get notified when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.

Latest updates to the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page’s revision label changed from v3.6.4 to v3.6.5, signaling a software update to the page without altering study data.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page shows a site revision update from v3.6.3 to v3.6.4, signaling a site-wide update. This change does not alter the content of the trial record or its history entries.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision: v3.6.3 was added and Revision: v3.6.2 was removed in the history. This represents a versioning update to the page history rather than a modification to trial data or core content.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page footer now shows Revision: v3.6.2, replacing the previous v3.6.0. This reflects a software update to the ClinicalTrials.gov interface and does not modify the study history data.SummaryDifference0.0%

- Check66 days agoChange DetectedThe study history now shows that enrollment is closed (no longer looking for participants) and adds a new revision entry (v3.6.0), with the previous revision (v3.5.5) removed from the record.SummaryDifference0.2%

- Check73 days agoChange DetectedA new site revision label v3.5.5 was added, replacing the previous v3.5.4 in the record history. This indicates a minor system or UI update and does not change study data or content.SummaryDifference0.0%

Stay in the know with updates to NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Enter your email address, and we'll notify you when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.